Hostname: page-component-848d4c4894-2pzkn Total loading time: 0 Render date: 2024-06-09T07:53:00.980Z Has data issue: false hasContentIssue false

A Prospective Post-Marketing Observational Study of Brivaracetam in People With Focal Epilepsy

Published online by Cambridge University Press:  27 December 2023

Rayan Yanes
Affiliation:
Faculty of Medicine, Université de Montréal, Montréal, QC, Canada
Joel Neves Briard
Affiliation:
Department of Neuroscience, Université de Montréal, Montréal, QC, Canada
Tang-Duc Jeremy Nguyen
Affiliation:
Faculty of Medicine, Université de Montréal, Montréal, QC, Canada
Maya Sultanem
Affiliation:
Faculty of Medicine, Université de Montréal, Montréal, QC, Canada
Dang Khoa Nguyen
Affiliation:
Department of Neuroscience, Université de Montréal, Montréal, QC, Canada Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM), Montréal, QC, Canada
Steve Gibbs
Affiliation:
Department of Neuroscience, Université de Montréal, Montréal, QC, Canada
Kristin Ikeda
Affiliation:
Division of Neurology, Dalhousie Medical School, Halifax, NS, Canada
Jeffrey Jirsch
Affiliation:
Division of Neurology, University of Toronto, Toronto, ON, Canada
Colin Josephson
Affiliation:
Division of Neurology, University of Calgary, Calgary, AB, Canada
Lysa Boisse Lomax
Affiliation:
Division of Neurology, Queen’s University, Kingston, ON, Canada
Véronique Cloutier
Affiliation:
Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM), Montréal, QC, Canada
Mark Keezer*
Affiliation:
Department of Neuroscience, Université de Montréal, Montréal, QC, Canada Centre de recherche du Centre hospitalier de l’Université de Montréal (CRCHUM), Montréal, QC, Canada École de santé publique de l’Université de Montréal, Montréal, QC, Canada
*
Corresponding author: M. Keezer; Email: mark.keezer@umontreal.ca

Abstract:

We evaluated the effectiveness and tolerability of brivaracetam (BRV), an adjunctive antiseizure medication, as a treatment for focal epilepsy in adults. In this prospective study, we enrolled 51 participants from 3 sites across Canada. At 6 months, 68% (26/38) of participants were still taking BRV, among whom 35% (8/23) attained seizure freedom and 48% (11/23) saw their seizure frequency reduced by over 50%. We did not measure any significant change in irritability, quality of life, depression, and anxiety while treated with BRV. Our findings suggest BRV is effective in reducing seizure frequency among adults with focal epilepsy.

Résumé :

RÉSUMÉ :

Nous avons cherché à évaluer l’efficacité et la tolérabilité du brivaracétam, un médicament anticonvulsivant d’appoint utilisé chez les adultes dans le traitement de l’épilepsie focale. Dans cette étude prospective, nous avons ainsi recruté 51 participants présents dans trois sites au Canada. Après 6 mois, 68 % (26/38) des participants prenaient toujours du brivaracétam, parmi lesquels 35 % (8/23) n’avaient plus de crises et 48 % (11/23) avaient vu la fréquence de leurs crises réduite de plus de 50 %. À noter que nous n’avons pas mesuré de changement significatif dans le niveau d’irritabilité, la qualité de vie, la dépression et l’anxiété des patients au cours de leur traitement au moyen du brivaracétam. Nos résultats suggèrent donc que ce médicament est efficace pour réduire la fréquence des crises convulsives chez les adultes souffrant d’épilepsie focale.

Type
Brief Communication
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ben-Menachem, E, Mameniskiene, R, Quarato, PP, et al. Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies. Neurology. 2016;87:314–23.Google ScholarPubMed
Biton, V, Berkovic, SF, Abou-Khalil, B, Sperling, MR, Johnson, ME, Lu, S. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia. 2014;55:5766.CrossRefGoogle ScholarPubMed
Klein, P, Schiemann, J, Sperling, MR, et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 2015;56:1890–8.CrossRefGoogle ScholarPubMed
Ryvlin, P, Werhahn, KJ, Blaszczyk, B, Johnson, ME, Lu, S. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia. 2014;55:4756.CrossRefGoogle ScholarPubMed
Delgado-Rodríguez, M, Llorca, J. Bias. J Epidemiol Community health. 2004;58:635–41.Google ScholarPubMed
von Elm, E, Altman, DG, Egger, M, Pocock, SJ, Gøtzsche, PC, Vandenbroucke, JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61:344–9.CrossRefGoogle ScholarPubMed
Holtzman, S, O’Connor, BP, Barata, PC, Stewart, DE. The brief irritability test (BITe): a measure of irritability for use among men and women. Assessment. 2015;22:101–15.Google Scholar
Spitzer, RL, Kroenke, K, Williams, JB, Löwe, B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166:1092–7.CrossRefGoogle ScholarPubMed
Gilliam, FG, Barry, JJ, Hermann, BP, Meador, KJ, Vahle, V, Kanner, AM. Rapid detection of major depression in epilepsy: a multicentre study. Lancet Neurol. 2006;5:399405.Google ScholarPubMed
Cramer, JA, Perrine, K, Devinsky, O, Meador, K. A brief questionnaire to screen for quality of life in epilepsy: the QOLIE-10. Epilepsia. 1996;37:577–82.Google ScholarPubMed
Supplementary material: File

Yanes et al. supplementary material

Yanes et al. supplementary material

Download Yanes et al. supplementary material(File)
File 26.5 KB